DOCSLIB.ORG

How Does Health Connect Us All?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
How Does Health Connect Us All? How does health connect us all? AstraZeneca Annual Report and Form 20-F Information 2010 Financial highlights $33.3bn Sales unchanged at $33,269 million ($32,804 million in 2009) $13.6bn Core operating profit unchanged at $13,603 million ($13,621 million in 2009) $6.71 Core EPS for the full year increased by 5% to $6.71 ($6.32 in 2009) $2.1bn Net share repurchases totalled $2,110 million ($nil in 2009) Important information for readers of this Annual Report and Form 20-F Information Statements of competitive position, growth rates and sales In this Annual Report, except as otherwise stated, market information regarding the position Cautionary statement regarding forward-looking statements of our business or products relative to its or their competition is based upon published The purpose of this Annual Report is to provide information to the members of the Company. statistical sales data for the 12 months ended 30 September 2010 obtained from IMS Health, The Company and its Directors, employees, agents and advisors do not accept or assume a leading supplier of statistical data to the pharmaceutical industry. For the US, dispensed responsibility to any other person to whom this Annual Report is shown or into whose hands new or total prescription data and audited sales data are taken, respectively, from IMS Health it may come and any such responsibility or liability is expressly disclaimed. In order, among National Prescription Audit and IMS National Sales Perspectives for the 12 months ended other things, to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation 31 December 2010; such data is not adjusted for Medicaid and similar state rebates. Except as Reform Act of 1995 and the UK Companies Act 2006, we are providing the following otherwise stated, these market share and industry data from IMS Health have been derived by cautionary statement: This Annual Report contains certain forward-looking statements with comparing our sales revenue to competitors’ and total market sales revenues for that period. respect to the operations, performance and financial condition of the Group. Forward-looking Except as otherwise stated, growth rates are given at CER. For the purposes of this Annual statements are statements relating to the future which are based on information available at Report, unless otherwise stated, references to the world pharmaceutical market or similar the time such statements are made, including information relating to risks and uncertainties. phrases are to the 44 countries contained in the IMS Health MIDAS Quantum database, which Although we believe that the forward-looking statements in this Annual Report are based on amounted to approximately 96% (in value) of the countries audited by IMS Health. reasonable assumptions, the matters discussed in the forward-looking statements may be influenced by factors that could cause actual outcomes and results to be materially different AstraZeneca websites from those expressed or implied by these statements. The forward-looking statements reflect Information on or accessible through our websites, including astrazeneca.com, knowledge and information available at the date of the preparation of this Annual Report and astrazenecaclinicaltrials.com and medimmune.com, does not form part of and is not the Company undertakes no obligation to update these forward-looking statements. We incorporated into this Annual Report. identify the forward-looking statements by using the words ‘anticipates’, ‘believes’, ‘expects’, External/third party websites ‘intends’ and similar expressions in such statements. Important factors that could cause actual Information on or accessible through any third party or external website does not form part results to differ materially from those contained in forward-looking statements, certain of which of and is not incorporated into this Annual Report. are beyond our control, include, among other things, those factors identified in the Principal risks and uncertainties section from page 96 of this Annual Report. Nothing in this Annual Definitions Report should be construed as a profit forecast. The Glossary and the Market definitions table from page 217 are intended to provide a useful guide to terms and AstraZeneca’s definition of markets, as well as to acronyms Inclusion of reported performance, Core financial measures and constant exchange and abbreviations used in this Annual Report. They are, however, provided solely for the rate growth rates convenience of the reader and should therefore not be relied upon as providing a definitive For further information in relation to the inclusion of reported performance, Core financial view of the subject matter to which they relate. measures and constant exchange rate (CER) growth rates as used in the Overview from page 2 and throughout the Business Review and Corporate Governance from pages 24 and 94 Use of terms respectively, please refer to the Financial Review section on page 80. In this Annual Report and Form 20-F Information, unless the context otherwise requires, ‘AstraZeneca’, ‘the Group’, ‘we’, ‘us’ and ‘our’ refer to AstraZeneca PLC and its consolidated Throughout this Annual Report, growth rates are expressed at CER unless otherwise stated. entities and any reference to ‘this Annual Report’ is a reference to this Annual Report and Form AstraZeneca’s determination of non-GAAP measures together with our presentation of 20-F Information. them within our financial information may differ from similarly titled non-GAAP measures Statements of dates of other companies. Except as otherwise stated, references to days and/or months in this Annual Report are references to days and/or months in 2010. Figures Figures in parentheses in tables and in the Financial Statements are used to represent negative numbers. Health is something Overview that connects us all In our mission to make a meaningful difference to the world’s health, we work closely with governments and regulators, Business Review those who pay for healthcare, our partners in industry and academia, and doctors. Through our activities we touch a great number of people’s lives and we are acutely conscious of our responsibility to patients and society in general. Corporate Governance Welcome to our 2010 Annual Report astrazeneca.com/ You will find this Annual Report and all the case annualreport2010 studies featured in this document on our website, astrazeneca.com/annualreport2010 Financial Statements Contents 2 Overview 50 Therapy Area Review 2 AstraZeneca at a glance 70 Geographical Review 4 Our year in brief 75 Other Businesses 6 Chairman’s Statement 78 Financial Review 8 Chief Executive Officer’s Review 10 Our Strategy and Performance 94 Corporate Governance 10 Our marketplace 94 Risk 14 Our strategy 106 Board of Directors and Senior Directors’ Report 18 Performance in 2010 Executive Team The following sections comprise 20 Life-cycle of a medicine 109 Corporate Governance Report the Directors’ Report which has been 119 Directors’ Remuneration Report prepared in accordance with the 24 Business Review requirements of the Companies Act 2006: 24 Delivering our strategy 135 Financial Statements Additional Information 26 Research and Development 135 Financial Statements 30 Intellectual Property > Our Strategy and Performance 32 Sales and Marketing 205 Additional Information > Business Review 34 Supply and Manufacturing 206 Development Pipeline > Corporate Governance 36 People 211 Shareholder Information > Development Pipeline 40 Responsible Business 216 Corporate Information > Shareholder Information 217 Glossary > Corporate Information 220 Index AstraZeneca Annual Report and Form 20-F Information 2010 Contents 1 AstraZeneca at a glance Who we are What we do We discover, develop and commercialise prescription medicines for six important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology and 6 Respiratory & Inflammation Focus on six areas of healthcare We have a broad range of medicines that includes established treatments for many serious illnesses, such as our antibiotic, Merrem/Meronem and Losec/Prilosec for 61,000 acid-related diseases 61,000 employees worldwide We use our scientific and commercial skills to develop a pipeline of innovative new medicines to meet medical need We had 10 medicines with sales of more than 10 $1 billion each in 2010 10 medicines with sales of over $1 billion in 2010 Cardiovascular Crestor for managing cholesterol levels Seloken/Toprol-XL 100 for hypertension, heart failure and angina Active in over 100 countries Atacand for hypertension and heart failure AstraZeneca is a focused, integrated, Gastrointestinal innovation-driven, global, prescription-based Nexium biopharmaceutical business for acid reflux Our mission is to make a meaningful Infection difference to patient health through Synagis great medicines for RSV, a respiratory infection in infants Neuroscience We are committed to acting responsibly Seroquel IR and to the sustainable development of for schizophrenia and bipolar disorder our business Seroquel XR for schizophrenia, bipolar disorder and major depressive disorder Our mission requires us to do things in the right way – to behave in accordance with Oncology our values and to act with integrity Arimidex for breast cancer We believe that our approach delivers lasting Zoladex value for patients, society and our shareholders for prostate and breast cancer Respiratory & Inflammation Symbicort for asthma and chronic obstructive pulmonary disease 2 AstraZeneca at a glance
Load more

Recommended publications
  • Jefferies 2013 Global Healthcare Conference in London
    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Misinterpretation of Time-To-First Event Curves Can Lead to Inappropriate Treatment
    AGORA | CORRESPONDENCE Misinterpretation of time-to-first event curves can lead to inappropriate treatment To the Editor: Great care should be taken when assessing the consistency of treatment effect over time based on a survival curve plot, and even more so when a treatment affects a repeating event end-point, such as exacerbations, rather than an event that can occur only once, like death. In their recent editorial in the European Respiratory Journal,SUISSA and ARIEL [1] make the assertation that survival functions plotted from Kaplan–Meier estimates from figure 1b in the IMPACT study [2] “clearly show that the difference in the rate of exacerbation between LAMA/LABA/ICS and LAMA/LABA over follow-up is due to the first month’s surge, with practically no differences in the subsequent rates between the two groups”. However, this statement is based on a misunderstanding of the survival analyses presented. The events plotted on the figure are the first moderate or severe COPD exacerbations experienced by a patient in the IMPACT study. The statements made by SUISSA and ARIEL [1] about exacerbation rates refer to the rate of first exacerbations only, and not to the rate of all exacerbations during the study. Their conclusion that the rates of first exacerbations, and ratio between those rates changes over time is correct. However, this is entirely in line with statistical theory for repeated events with overall constant rates. It cannot be used to support any conclusion that the difference in the rate of exacerbation is due to a “first month’s surge”. The “digitised” curve of first events behaves entirely consistently with constant rate events.
    [Show full text]
  • International Smallcap Separate Account As of July 31, 2017
    International SmallCap Separate Account As of July 31, 2017 SCHEDULE OF INVESTMENTS MARKET % OF SECURITY SHARES VALUE ASSETS AUSTRALIA INVESTA OFFICE FUND 2,473,742 $ 8,969,266 0.47% DOWNER EDI LTD 1,537,965 $ 7,812,219 0.41% ALUMINA LTD 4,980,762 $ 7,549,549 0.39% BLUESCOPE STEEL LTD 677,708 $ 7,124,620 0.37% SEVEN GROUP HOLDINGS LTD 681,258 $ 6,506,423 0.34% NORTHERN STAR RESOURCES LTD 995,867 $ 3,520,779 0.18% DOWNER EDI LTD 119,088 $ 604,917 0.03% TABCORP HOLDINGS LTD 162,980 $ 543,462 0.03% CENTAMIN EGYPT LTD 240,680 $ 527,481 0.03% ORORA LTD 234,345 $ 516,380 0.03% ANSELL LTD 28,800 $ 504,978 0.03% ILUKA RESOURCES LTD 67,000 $ 482,693 0.03% NIB HOLDINGS LTD 99,941 $ 458,176 0.02% JB HI-FI LTD 21,914 $ 454,940 0.02% SPARK INFRASTRUCTURE GROUP 214,049 $ 427,642 0.02% SIMS METAL MANAGEMENT LTD 33,123 $ 410,590 0.02% DULUXGROUP LTD 77,229 $ 406,376 0.02% PRIMARY HEALTH CARE LTD 148,843 $ 402,474 0.02% METCASH LTD 191,136 $ 399,917 0.02% IOOF HOLDINGS LTD 48,732 $ 390,666 0.02% OZ MINERALS LTD 57,242 $ 381,763 0.02% WORLEYPARSON LTD 39,819 $ 375,028 0.02% LINK ADMINISTRATION HOLDINGS 60,870 $ 374,480 0.02% CARSALES.COM AU LTD 37,481 $ 369,611 0.02% ADELAIDE BRIGHTON LTD 80,460 $ 361,322 0.02% IRESS LIMITED 33,454 $ 344,683 0.02% QUBE HOLDINGS LTD 152,619 $ 323,777 0.02% GRAINCORP LTD 45,577 $ 317,565 0.02% Not FDIC or NCUA Insured PQ 1041 May Lose Value, Not a Deposit, No Bank or Credit Union Guarantee 07-17 Not Insured by any Federal Government Agency Informational data only.
    [Show full text]
  • Jefferies 2014 Global Healthcare Conference in London
    Jefferies 2014 Global Healthcare Conference in London You are invited to attend the Jefferies Global Healthcare Conference on 19-20 November, 2014, at the Waldorf Hilton in London. Now in its fifth year, ours is the largest healthcare-dedicated conference in Europe. Last year, we had 230 participating healthcare companies with a combined market capitalisation of over INVITATION $1 trillion and close to 2,250 1x1/small-group meetings. The 2014 conference is set to follow 19-20 NOVEMBER 2014 in the same footsteps, featuring leading public and private companies from areas of The Waldorf Hilton pharmaceuticals, biotechnology, generics, consumer health, animal health, medical London, UK technology and healthcare services from the United States, Western and Emerging Europe, Middle East & Africa, Latin America, Russia, India, Israel, China, and Japan. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative © 2014 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, NOVEMBER 19, 2014 Jefferies 2014 Global Healthcare Conference in London TRACK 1 TRACK 2 TRACK 3 TRACK 4 TRACK 5 ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM ALDWYCH 7:30 AM Breakfast and Registration 8:00 AM EMIS Group PLC( AIM:EMIS) Auris Medical Holding AG Sartorius AG (DB:SRT) Medivation, Inc.(NasdaqGS:MDVN) Ethypharm SA (Private) Healthcare Technology (NasdaqGM:EARS) Medical Products & Devices Biotechnology Pharmaceuticals Chris Spencer, CEO Pharmaceuticals Joerg Pfirrmann, CFO David Hung, M.D., President and CEO Hugues Lecat, CEO and Chairman of the Dr.
    [Show full text]
  • BTG Plc Annual Report Annual Plc BTG and Accounts 2014 Imagine Where We Can Go
    BTG plc Annual Report and Accounts 2014 BTG plc Annual Report and Accounts 2014 Imagine where we can go. Introduction BTG is a growing international specialist healthcare company. We develop innovative products in specialist areas of medicine where current treatment options are limited. Our products advance the treatment of people with liver cancer, blood clots and varicose veins, and of people who need antidotes if they are overexposed to certain medications or toxins. Inspired by patient need, we are investing to expand our portfolio with products that address today’s healthcare challenges. Partnership and innovation are at the heart of our approach. By delivering products that improve patient treatment, and that are valued by clinicians and payers, we will grow our business sustainably and will deliver significant value to all our stakeholders. Imagine where we can go. Find out more online www.btgplc.com Strategic report Our performance 02 An overview of our performance Group overview 04 this year, our business model, Chairman’s statement 06 our objectives and the principal risks Chief Executive’s review 08 we face, accompanied by relevant Our objectives 10 performance and operating information. Focus on Interventional Medicine: Vascular 14 Focus on Interventional Medicine: Oncology 16 Our business model 18 Read more page 03 Corporate citizenship 22 Market overview 24 Financial review 26 Risk management and principal risks 30 Governance Board of Directors 36 The Board of Directors and our Corporate governance report 38 approach to corporate governance Audit Committee report 46 and remuneration. Nomination Committee report 50 Directors’ remuneration report 51 Directors’ report 69 Statement of directors’ responsibilities 71 Read more page 35 Independent auditor’s report 72 Strategic report Strategic report Financials Consolidated income statement 76 Financial statements, notes Consolidated statement of comprehensive income 77 and other key data.
    [Show full text]
  • Aqua Bounty Technologies ABTX Pharmaceuticals & Biotechnology — USD 0.125 at Close 19 November 2015
    FTSE COMPANY REPORT Share price analysis relative to sector and index performance Data as at: 19 November 2015 Aqua Bounty Technologies ABTX Pharmaceuticals & Biotechnology — USD 0.125 at close 19 November 2015 Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 19-Nov-2015 19-Nov-2015 19-Nov-2015 0.18 120 120 1D WTD MTD YTD Absolute 0.0 0.0 0.0 -26.5 0.17 110 110 Rel.Sector -0.3 -4.9 0.3 -25.6 Rel.Market -0.7 -3.0 0.4 -25.2 0.16 100 100 VALUATION (local currency) (local 0.15 90 90 Trailing Relative Price Relative Price 0.14 80 80 PE -ve Absolute Price Price Absolute EV/EBITDA -ve 0.13 70 70 PCF -ve PB 8.7 0.12 60 60 Price/Sales - Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Div Yield 0.0 Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Div Payout 0.0 100 90 100 ROE -ve 90 80 90 Net Debt/Equity 0.7 80 70 80 70 70 60 60 60 DESCRIPTION 50 50 50 40 The Company engages in research, develop and 40 40 RSI (Absolute) RSI 30 commercialize products that improve aquaculture 30 30 productivity. The Company focuses on improving 20 20 20 productivity in the aquaculture market 10 10 10 RSI (Relative to FTSE UK All-Share Index) UK All-Share to FTSE (Relative RSI RSI (Relative to FTSE UK All-Share Sector) UK All-Share to FTSE (Relative RSI 0 0 0 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 Nov-2014 Feb-2015 May-2015 Aug-2015 Nov-2015 See final page and http://www.londonstockexchange.com/prices-and-markets/stocks/services-stock/ftse-note.htm for further details.
    [Show full text]
  • 2018 SIR Annual Scientific Meeting Faculty Financial Disclosures
    2018 SIR Annual Scientific Meeting Faculty Financial Disclosures Mohamed H.K. Abdelmaksoud Other: Proctor; Consultant: SIRTEX, Merit Medical Inc.; Advisory committee or review panel member: Merit medical Inc. J. Fritz Angle Consultant: Proteon, Dahchi Sankyo; Research grant recipient: Siemens Medical Hussein Aoun Consultant: BTG Medical Yasuaki Arai Royalties: Piolax Medical Devices, Sumitomo Bakelite Co., Ltd; Research grant recipient: Terumo Corporation,Toshiba Medical Systems, Taiho Pharmaceutical, Eisai Co., Ltd.; Advisory committee or review panel member: Eisai Inc; Speaking and teaching: Merit Medical Systems, Fuji Pharma Co., Ltd. ,Terumo International Systems, Nippon Kayaku, Toshiba Medical Systems, Bristol Meyer Squibb, Sumitomo Bakelite Co., Ltd., Bayer Pharmaceuticals, Boston Scientific Japan, Taiho Pharmaceutical, Guerbet Japan, Guerbet Asia Pacific Aravind Arepally Intellectual property rights: Surefire Medical; Consultant: SirTex Medical Bulent Arslan Advisory committee or review panel member: Medtronic; Speaking and teaching: Medtronic, Boston Scientific, Cook, Penumbra Jung Hwan Baek Consultant: STARmed (2017-2018), RF medical (2017 only) Sandeep Bagla Consultant: Medtronic, Boston Scientific, Teleflex, Terumo, Merit; Research grant recipient: Medtronic, Boston Scientific, Terumo, BTG, Renovo Giacomo Basadonna Board membership: Alira Health Douglas Beall Consultant: Benvenue, Lilly, Amendia, Medtronic; Speaking and teaching: Benvenue, Lilly, Medtronic; Board membership: SIR, Vexim, Lilly, Amendia, Medtronic; Ownership
    [Show full text]
  • UK's Global Bioscience Cluster 2016 the UK Bioindustry Association: Delivering the Best Possible Environment for Biotechnology Growth and Innovation
    Building something great: UK's Global Bioscience Cluster 2016 The UK BioIndustry Association: Delivering the best possible environment for biotechnology growth and innovation. We advocate to government at both the UK and European levels to improve policies, funding and taxation. We also work to improve the business environment by engaging with regulators, the City, venture capitalists, charities and patient groups. Join now: 320 members, 135 companies represented on Advisory Committees Save: Our members saved over £5.8M in 2016 through our Business Solutions programme Connect: Network and build relationships with 2,500+ industry leaders at our UK-wide events Influence: Be at the heart of policy development. Shape our sector and represent positive change for UK biotech Join UK’s trade association for biotechnology now: www.bioindustry.org/membership Contents Foreword from UK BioIndustry Association Chief Executive, Steve Bates, OBE 4 Foreword from Informa Pharma Executive Editor, John Hodgson 5 Overall trends for UK biotech in 2016 7 Venture capital funding 9 The UK venture capital picture has matured 9 Top UK venture capital rounds 2016 11 Venture capital raised – rest of Europe and USA 14 Public markets 16 UK IPOs 2016 16 Changes in global public markets for UK biotech 19 AIM persists as a source of follow-on finance, even when markets are more closed 21 Partnering and deal making 24 Selected acquisition by UK companies in 2016 24 Pipeline 28 The future 30 Updated 22 September 2017 Foreword from UK BioIndustry Association Chief Executive, Steve Bates, OBE The UK has some of the world’s most exciting science, a supportive business environment, and strong companies led by experienced management teams.
    [Show full text]
  • Annual Report 2012
    Registered office and Investor relations Registrar US Depositary 2012 20-F Information Form and Report Annual AstraZeneca AstraZeneca Annual Report corporate headquarters [email protected] Equiniti Limited JPMorgan Chase & Co and Form 20-F Information 2012 AstraZeneca PLC Aspect House PO Box 64504 2 Kingdom Street UK: as above Spencer Road St Paul London W2 6BD Lancing MN 55164-0504 UK US West Sussex BN99 6DA US Tel: +44 (0)20 7604 8000 Investor Relations UK Tel: (toll free in the US) Fax: +44 (0)20 7604 8151 AstraZeneca Pharmaceuticals LP Tel: (freephone in the UK) 888 697 8018 1800 Concord Pike 0800 389 1580 Tel: (outside the US) PO Box 15437 Tel: (outside the UK) +1 (651) 453 2128 Wilmington +44 (0)121 415 7033 [email protected] DE 19850-5437 US Swedish Central Securities Tel: +1 (302) 886 3000 Depository Fax: +1 (302) 886 2972 Euroclear Sweden AB PO Box 191 SE-101 23 Stockholm Sweden Tel: +46 (0)8 402 9000 Delivering value This Annual Report is also available on through innovation our website, astrazeneca.com/ annualreport2012 Important information for readers of this Annual Report AstraZeneca Cautionary statement regarding Innovation is at the core of everything we forward-looking statements Welcome to the AstraZeneca The purpose of this Annual Report is to provide Annual Report and Form information to the members of the Company. The do at AstraZeneca – from our research 20-F Information 2012 Company and its Directors, employees, agents and (Annual Report). You will find advisers do not accept or assume responsibility to into effective new medicines to how we this Annual Report on our any other person to whom this Annual Report is website, astrazeneca.com/ shown or into whose hands it may come and any annualreport2012 such responsibility or liability is expressly disclaimed.
    [Show full text]
  • UK Specialty Pharma Companies Outperform Biotech
    September 18, 2008 UK specialty pharma companies outperform biotech Amy Brown Shares in companies judged to be risky prospects have performed poorly this year, and the life sciences sector has been hit particularly badly by increasingly risk-averse investors. In particular, the fate of small biotechnology companies has not been pretty; even an absence of news, as opposed to actual clinical failure, has been enough to send share prices tumbling. Specialty pharma companies, however, have escaped such a severe mauling. This bodes well for BTG, which this morning announced the acquisition of fellow UK company Protherics, with the aim of giving its specialty pharma ambitions a boost. The table below shows the performance of UK listed biotechnology and specialty pharma companies. While both groups have declined, an investor more heavily exposed to the latter group will be doing considerably better. With their lower risk business model and a more realistic chance of achieving profitability, this is not too surprising. Specialty pharma will focus on later stage products, leaving the high risk R&D to someone else. This is exactly what BTG plans to do following the acquisition of Protherics. Over the next few months, the group will be culling early stage projects from the pipeline, while looking for niche, late stage products to acquire. Given the early stage of the deal, full plans have not yet been announced, but some commentators questioned the lack of a definite therapeutic focus emerging. If the deal proceeds, an update should be given alongside preliminary results in May, and investors will be looking out for a more defined strategy.
    [Show full text]
  • Philipp Dohnke
    Philipp Dohnke Partner Corporate and M&A, Intellectual property Primary practice Corporate and M&A, Intellectual property 25/09/2021 Philipp Dohnke | Freshfields Bruckhaus Deringer About Philipp Dohnke <p><strong>Philipp is a member of our intellectual property and information technology team. </strong></p> <p>Since joining the firm, he has worked across many industries with a particular focus on life science and technologies. Philipp has broad expertise&nbsp;in complex, high-profile transactions, including large carve-out and asset deal projects. In addition, Philipp is experienced in drafting and negotiating complex commercial contracts.</p> <div> <p>He&nbsp;speaks German and English.</p> </div> Recent work <ul> <li>Apax and Warburg Pincus on their &euro;5,1bn acquisition of T-Mobile Netherlands</li> <li>Osram on the cave-out and sale of its Digital Systems business in North America to Acuity</li> <li>Thermo Fisher on its &euro;725m acquisition of the viral vector manufacturing business of Novasep (Belgium)</li> <li>AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals</li> <li>Charterhouse / Serb on the $800m acquisition of the BTG Specialty Pharmaceuticals business from Boston Scientific Corporation</li> <li>Novartis on its $5.2bn acquisition of pharmaceutical product Xiidra from Takeda/Shire</li> <li>Merck on its &euro;3.4bn carve-out und sale of its consumer health business to Procter &amp; Gamble</li> <li>Boehringer Ingelheim on its &euro;18bn business swap with Sanofi (Consumer Healthcare against Animal Health)</li> <li>Boehringer
    [Show full text]